CLINICAL TRIALS PROFILE FOR LY3549492
Clinical Trials for LY3549492
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04758234 ↗ | A Study of LY3549492 in Healthy Participants | Recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening. |
| NCT05327595 ↗ | A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM) | Not yet recruiting | Eli Lilly and Company | Phase 1 | The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part. |
| NCT06194500 ↗ | A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 ([14C] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive [14C] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits. |
| NCT06683508 ↗ | A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight | ACTIVE_NOT_RECRUITING | Eli Lilly and Company | PHASE2 | The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year. |
| NCT06869018 ↗ | A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants | RECRUITING | Eli Lilly and Company | PHASE1 | The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening. |
| NCT07030868 ↗ | A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | TERMINATED | Eli Lilly and Company | PHASE2 | The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months. |
| NCT07073170 ↗ | A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus | NOT_YET_RECRUITING | Eli Lilly and Company | PHASE1 | The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY3549492
Condition Name
Clinical Trial Locations for LY3549492
Trials by Country
Clinical Trial Progress for LY3549492
Clinical Trial Phase
Clinical Trial Sponsors for LY3549492
Sponsor Name
